SimulAD Modeled Amyloid Clearance in Alzheimer’s Trials
TL;DR: A 2026 medRxiv preprint tested SimulAD, an Alzheimer’s disease progression simulator, and reported that it reproduced mean amyloid-clearance results within 5% error across six major phase III anti-amyloid trials while also separating positive trials fro…
Read article